Semiz Murat, Yücel Hasan, Kavakçı Onder, Yıldırım Osman, Zorlu Ali, Yılmaz Mehmet Birhan, Küçükdurmaz Zekeriya, Canan Fatih
Psychiatry Clinic, Sivas Numune Hospital, Sivas, Turkey.
Department of Cardiology, Cumhuriyet University School of Medicine, Sivas, Turkey.
J Res Med Sci. 2013 Jul;18(7):561-6.
Cardiovascular diseases, cardiovascular risk factors, and mortality due to these situations are more frequently encountered in schizophrenic patients when compared with the general population. The mean platelet volume (MPV) is a surrogate biomarker of the platelet activity and an useful prognostic test in cardiometabolic diseases. The aim of this study was to investigate what influenced MPV levels in patients with schizophrenia.
We evaluated hospital records of 60 hospitalized schizophrenia patients. Thirty age- and sex-matched healthy control subjects were also included as a control group.
MPV levels were significantly higher in patients who were on atypical antipsychotic drugs than in patients who were not using any drug (9.2 ± 0.8 vs. 8.6 ± 0.8 fL, P = 0.016) and also higher than control group (9.2 ± 0.8 vs. 8.1 ± 0.9 fL, P < 0.001). Furthermore, patients who were not using antipsychotics had higher MPV than control group (8.6 ± 0.8 vs. 8.1 ± 0.9 fL, P = 0.036). Atypical antipsychotic use [Odds ratio (OR) =6.152, 95% confidence interval (CI,) P = 0.003)] and platelet distribution width (OR = 0.989, 95% CI, P = 0.032) were associated with high MPV levels in univariate analysis. In multivariate logistic regression model, only atypical antipsychotics use (OR = 6.152, 95% CI, P = 0.003) was found to be independent predictor of high MPV levels after adjustment of other potential confounders (age, gender, presence of hypertension, diabetes mellitus, hyperlipidemia, and smoking).
MPV seems to be influenced not only by schizophrenia itself but also by atypical antipsychotic drugs. It might be concluded that schizophrenic patients are under increased risk for cardiometabolic diseases and risk factors and this risk is higher in patients on atypical antipsychotic treatment.
与普通人群相比，心血管疾病、心血管危险因素以及由这些情况导致的死亡率在精神分裂症患者中更为常见。平均血小板体积（MPV）是血小板活性的替代生物标志物，也是心血管代谢疾病中一种有用的预后检测指标。本研究的目的是调查影响精神分裂症患者MPV水平的因素。
我们评估了60例住院精神分裂症患者的医院记录。还纳入了30名年龄和性别匹配的健康对照者作为对照组。
使用非典型抗精神病药物的患者MPV水平显著高于未使用任何药物的患者（9.2±0.8 vs. 8.6±0.8 fL，P = 0.016），也高于对照组（9.2±0.8 vs. 8.1±0.9 fL，P < 0.001）。此外，未使用抗精神病药物的患者MPV高于对照组（8.6±0.8 vs. 8.1±0.9 fL，P = 0.036）。在单因素分析中，使用非典型抗精神病药物[比值比（OR）=6.152，95%置信区间（CI），P = 0.003]和血小板分布宽度（OR = 0.989，95% CI，P = 0.032）与高MPV水平相关。在多因素逻辑回归模型中，在调整其他潜在混杂因素（年龄、性别、高血压、糖尿病、高脂血症和吸烟）后，仅发现使用非典型抗精神病药物（OR = 6.152，95% CI，P = 0.003）是高MPV水平的独立预测因素。
MPV似乎不仅受精神分裂症本身影响，还受非典型抗精神病药物影响。可以得出结论，精神分裂症患者患心血管代谢疾病和危险因素的风险增加，且在接受非典型抗精神病药物治疗的患者中这种风险更高。
